Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KONFIDENT: Sebetralstat for HAE attacks
NCT05259917Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of sebetralstat in hereditary angioedema (HAE) (3 arms), sponsored by KalVista Pharmaceuticals. Primary endpoint: Time to Beginning of Symptom Relief Patient Global Impression of Change (PGI-C) at 12 hours. Started Feb 2022; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05259917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259917.